Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564571 · ClinicalTrials.gov registry record
Artificial Intelligence in Endoscopic Ultrasound
A clinical trial of Pancreatic Cancer and Pancreatic Cyst, sponsored by Orlando Health.
- Recruiting
- Registry status
- 310
- Enrollment target
- 1
- Study location
NCT06564571: Recruiting study of Pancreatic Cancer and Pancreatic Cyst, sponsored by Orlando Health.
NCT06564571 is a study of Pancreatic Cancer and Pancreatic Cyst that is actively recruiting participants, run by Orlando Health. The registered enrollment target is 310 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06564571, a study of Pancreatic Cancer and Pancreatic Cyst, is actively recruiting participants, sponsored by Orlando Health.
- RECRUITING
- Registry status
- 310 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.
Primary Outcome
Ability of AI to detect pancreatic abnormalities as identified by an endoscopist during EUS examination of the pancreas.
Conditions Studied
Interventions
- DEVICE Patients undergoing endoscopic ultrasound procedures
Study Locations (1)
Florida
- Orlando Health - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2024-01-19 |
| Est. Completion | 2027-12 |
What NCT06564571 shows while recruiting
NCT06564571 is an observational study that tracks outcomes without assigning an intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (21% lower).
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Patients undergoing endoscopic ultrasound procedures is the first listed.
NCT06564571 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06564571 about?
NCT06564571 is a clinical study titled "Artificial Intelligence in Endoscopic Ultrasound". The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.
What is the current status of trial NCT06564571?
This trial is currently recruiting. The enrollment target is 310 participants. The study started on 2024-01-19. Estimated completion is 2027-12.
What conditions does trial NCT06564571 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Cyst, Pancreas Disease.
What interventions are being tested in trial NCT06564571?
The interventions under investigation include: Patients undergoing endoscopic ultrasound procedures (DEVICE).
Who is sponsoring clinical trial NCT06564571?
This trial is sponsored by Orlando Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564571 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06564571's enrollment target sits among peer trials
310 50th of 278 higher than 229 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI